Xencor saw the highest growth of 1.79% in patent filings in May and 1.99% in grants in June in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.55% and grants by 0.32%. GlobalData’s DataBook provides a comprehensive analysis of Xencor‘s patent filings and grants. Buy the databook here.
Xencor has been focused on protecting inventions in European Patent Office(EPO) with seven publications in Q2 2024
The European Patent Office(EPO) Patent Office dominates the patent filings with nearly 35% of filings. The European Patent Office(EPO), World Intellectual Property Organization(WIPO), United States(US), and China(CN) patent Office are among the top ten patent offices where Xencor is filings its patents. Among the top granted patent authorities, Xencor has 50% of its grants in United States(US), 25% in Israel(IL) and 12% in China(CN).
Roche could be the strongest competitor for Xencor
Patents related to climate change and rare diseases lead Xencor's portfolio
Xencor has the highest number of patents in climate change followed by, rare diseases. For climate change, nearly 50% of patents were filed and 25% of patents were granted in Q2 2024.
Multiple myeloma (kahler disease) related patents lead Xencor portfolio followed by immunoglobulin g4-related disease (igg4-rd), and blood cancer
Xencor has highest number of patents in multiple myeloma (kahler disease) followed by immunoglobulin g4-related disease (igg4-rd), blood cancer, follicular lymphoma, and lymphoblastic lymphoma.
For comprehensive analysis of Xencor's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.